# A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

> **NCT02599363** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 18 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Ribociclib (LEE011)
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02599363
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-03-12
- **Final completion:** 2019-03-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599363, "A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02599363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*